JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell–Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive CancersKarine Smans(Johnson & Johnson (United States)), Paul R. Gavine(AstraZeneca (Poland))Molecular Cancer TherapeuticsMarch 3, 202610.1158/1535-7163.mct-25-0665Cited by 0SaveCiteExport RISWatch citationsRelated PapersVolitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models|Molecular Oncology|2014|120